Axa
GYRE icon

Axa’s Gyre Therapeutics GYRE Stock Holding History

Axa’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,560
Closed -$86K – 1325
2019
Q2 		$86K Sell
1,560
-2,307
-60% -$144K ﹤0.01% 1262
2019
Q1 		$235K Hold
3,867
– – ﹤0.01% 1241
2018
Q4 		$229K Hold
3,867
– – ﹤0.01% 1211
2018
Q3 		$313K Hold
3,867
– – ﹤0.01% 1222
2018
Q2 		$338K Buy
+3,867
New +$678K ﹤0.01% 1204

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Axa's GYRE Position: Q3 2019 in Review

Axa sold out of Gyre Therapeutics (GYRE) in Q3 2019, closing a stake of 1,560 shares — an estimated $86K sold.

Axa first reported a position in GYRE in Q2 2018 and held it in 5 quarters. The position peaked at $338K in Q2 2018. 42 funds tracked by Wall St. Rank hold GYRE as of Q3 2019.

  • Axa reported no remaining Gyre Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Axa sold 1,560 Gyre Therapeutics shares in Q3 2019, an estimated $86K.
  • Axa first reported a position in Gyre Therapeutics in Q2 2018 and held it in 5 quarters.
  • Axa's Gyre Therapeutics position peaked at $338K in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2019.

Based on Axa's 13F filing for Q3 2019, filed 14 Nov 2019.